Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) Research & Development (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Research & Development data on record, last reported at $312.8 million in Q1 2026.

  • On a quarterly basis, Research & Development rose 111.15% to $312.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $959.0 million, a 80.87% increase, with the full-year FY2025 number at $794.3 million, up 66.65% from a year prior.
  • Research & Development reached $312.8 million in Q1 2026 per PCVX's latest filing, up from $242.1 million in the prior quarter.
  • Over the last five years, Research & Development for PCVX hit a ceiling of $312.8 million in Q1 2026 and a floor of $31.7 million in Q1 2022.
  • A 5-year average of $122.7 million and a median of $104.2 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 133.4% in 2022, then grew 20.03% in 2024.
  • Tracing PCVX's Research & Development over 5 years: stood at $51.6 million in 2022, then soared by 101.74% to $104.2 million in 2023, then grew by 28.29% to $133.6 million in 2024, then soared by 81.16% to $242.1 million in 2025, then increased by 29.22% to $312.8 million in 2026.
  • Business Quant data shows Research & Development for PCVX at $312.8 million in Q1 2026, $242.1 million in Q4 2025, and $209.9 million in Q3 2025.